p-Cresyl Sulfate in CKD Cardiovascular Research

Executive Summary: p-Cresyl sulfate is the p-cresol-derived metabolite p-tolyl hydrogen sulfate with formula C₇H₈O₄S and CAS 3233-58-7, according to the product information. It is a protein-bound uremic retention solute whose circulating concentration increases as renal function declines, as reported in the reference study. Product data report dose-dependent inhibition of endothelial cell proliferation and wound repair without loss of cell viability. In isolated porcine valvular interstitial cells, 10 and 100 μM p-cresyl sulfate exposures for 7 days increased calcification. The same study associated this phenotype with reduced klotho and increased HIF-1α, NF-κB acetylation, and RUNX2 expression.

Biological Rationale

Chronic kidney disease reduces renal clearance of many endogenous and microbiota-derived solutes. p-Cresyl sulfate is generated from p-cresol and circulates as a strongly protein-bound uremic compound. The 2026 reference study identifies increasing circulating p-cresyl sulfate as renal function decreases and places the metabolite within the cardiovascular complications of CKD.

CKD is associated with a greater burden of calcific aortic valve disease than non-CKD status. The reference article reports calcific aortic valve disease in 28–85% of patients with CKD and severe aortic stenosis in 6–13% of patients with CKD, compared with a 1% prevalence of severe aortic stenosis in patients without CKD. These are reported clinical ranges rather than universal estimates because prevalence depends on the studied population and disease definition.

The biological rationale is therefore two-sided. First, retained p-cresyl sulfate can serve as a biomarker for uremia-related cardiovascular risk. Second, experimental exposure can model cellular responses relevant to endothelial dysfunction research and vascular complication studies. A biomarker association does not by itself prove that p-cresyl sulfate causes every cardiovascular manifestation of CKD.

Material profile

• Identity: p-Cresyl sulfate is also named p-tolyl hydrogen sulfate and has CAS 3233-58-7.
• Composition: The listed molecular formula is C₇H₈O₄S.
• Physical form: The product is described as a solid.
• Solubility: The product information reports solubility of at least 30.1 mg/mL in DMSO and at least 50 mg/mL in water, while ethanol is listed as an unsuitable solvent.
• Handling: Storage at −20°C and preparation of fresh solutions immediately before use are recommended because solution stability is limited.

These material specifications describe the A8895 research reagent supplied by APExBIO. They do not establish the chemical stability of every buffer, protein concentration, temperature, or exposure duration used in a laboratory.

Mechanism of Action of p-Cresyl sulfate

Endothelial and repair phenotypes

Product-supported in-vitro findings describe a dose-dependent reduction in endothelial cell proliferation after p-cresyl sulfate exposure. The same information reports reduced wound repair without a corresponding reduction in cell viability. This distinction matters because a slower scratch closure can reflect impaired migration or proliferation rather than nonspecific cytotoxicity.

Human serum albumin modifies the observed response in the described endothelial experiments. Albumin binding can change the free fraction available to cells. Consequently, total nominal concentration and biologically available concentration should not be treated as interchangeable experimental variables.

Valvular calcification pathway

The reference study tested isolated porcine valvular interstitial cells for 7 days. Exposure to p-cresyl sulfate at 10 or 100 μM increased Alizarin Red S-detectable calcification. Western blotting and related protein analyses showed increased HIF-1α, increased RUNX2, increased NF-κB acetylation, and reduced klotho under the reported conditions.

The study proposes a signaling sequence in which p-cresyl sulfate activates HIF-1α-associated responses and downregulates klotho. Klotho supplementation at 100 pM attenuated the increase in calcification, NF-κB acetylation, and RUNX2 reported in p-cresyl sulfate-treated cells. The SIRT1 activator SRT1720 at 1 mM also attenuated calcification and increased klotho while reducing RUNX2 in the reported cell model. These concentrations are study conditions, not validated therapeutic doses.

In a p-cresyl sulfate-treated rat CKD model, klotho supplementation mitigated CKD-associated RUNX2 upregulation in aortic valves. This in-vivo observation connects the cell phenotype to a renal-failure model, but it does not demonstrate clinical efficacy in human calcific aortic valve disease.

Evidence & Benchmarks

The following benchmarks distinguish product information from findings in the cited peer-reviewed study. Each item states the condition needed to interpret the result.

• p-Cresyl sulfate is listed as p-tolyl hydrogen sulfate with CAS 3233-58-7 and molecular formula C₇H₈O₄S in the product dossier: product information
• Porcine valvular interstitial cells exposed to p-cresyl sulfate at 10 or 100 μM for 7 days showed increased calcification by Alizarin Red S staining: https://doi.org/10.3892/mmr.2026.13872
• The same 7-day porcine cell study associated p-cresyl sulfate exposure with increased HIF-1α, RUNX2, and NF-κB acetylation and reduced klotho expression: https://doi.org/10.3892/mmr.2026.13872
• Klotho at 100 pM reduced p-cresyl sulfate-associated calcification and signaling changes in the reported porcine valvular interstitial cell model: https://doi.org/10.3892/mmr.2026.13872
• SRT1720 at 1 mM attenuated p-cresyl sulfate-associated calcification in the reported 7-day porcine valvular interstitial cell experiment: https://doi.org/10.3892/mmr.2026.13872
• Klotho supplementation mitigated RUNX2 upregulation in aortic valves from p-cresyl sulfate-treated rats with experimental CKD: https://doi.org/10.3892/mmr.2026.13872
• The product dossier reports reduced endothelial proliferation and wound repair without reduced viability in dose-dependent in-vitro experiments: product information
• Renal-failure rats showed altered p-cresyl sulfate pharmacokinetics and lower urinary excretion than rats with normal renal function in the described product-supported studies: product information

Applications, Limits & Misconceptions

Research applications

p-Cresyl sulfate can support controlled studies of uremic solute exposure, endothelial repair, and vascular mineralization. A scratch-wound assay can test closure kinetics, while a viability assay can determine whether reduced closure reflects cytotoxicity. Valvular interstitial cell experiments can pair Alizarin Red S staining with RUNX2, HIF-1α, klotho, and NF-κB-related measurements.

In chronic kidney disease models, the compound can be used to examine how impaired clearance changes cardiovascular phenotypes. Pharmacokinetic studies can compare circulating exposure and urinary elimination between renal-function states. Such experiments contribute to uremic toxin clearance research, but they should not assume that dialysis removes protein-bound solutes with the same efficiency as freely filtered compounds.

The compound is also useful in biomarker-oriented cardiovascular studies. Researchers should distinguish total plasma p-cresyl sulfate from the unbound fraction when albumin is present. The distinction is especially important when translating a nominal cell-culture concentration into a circulating exposure.

Common Pitfalls or Misconceptions

• It is not a universal diagnostic test. p-Cresyl sulfate can function as a research biomarker, but the cited evidence does not establish a standalone clinical diagnostic threshold for cardiovascular risk.
• It is not equivalent to p-cresol. p-Cresol is the precursor, whereas p-cresyl sulfate is the sulfated metabolite. Substituting one for the other changes chemical identity and biological interpretation.
• A nominal dose is not the free dose. Albumin can modulate cellular exposure. Total added concentration should therefore be reported separately from protein-binding conditions.
• Cell calcification is not human valve disease. The 7-day porcine cell findings and rat CKD model support mechanistic investigation, not proof of therapeutic benefit or human disease causality.
• Solubility is not stability. A solution that reaches a target concentration may still require immediate use, temperature control, and verification in the chosen assay matrix.

Related reading

p-Cresyl Sulfate: Mechanistic Insights and Translational Leverage introduces CKD, vascular complications, and klotho/SIRT1 signaling; this article extends that overview by separating product-handling facts from the 2026 valvular-cell benchmarks.

p-Cresyl Sulfate: Translating Uremic Toxin Biology Into Clinical Insight frames p-cresyl sulfate as a cardiovascular biomarker; this article clarifies the limits of that interpretation and adds specific calcification conditions from the cited reference study.

Workflow Integration & Parameters

A rigorous workflow should treat p-cresyl sulfate as both a chemical reagent and a protein-binding biological variable. Record product SKU A8895, lot information, solvent, preparation time, albumin concentration, cell type, exposure duration, and endpoint method. Use matched vehicle and untreated controls. Include a viability endpoint when interpreting proliferation or wound closure.

Protocol Parameters

• Storage: Store the solid reagent at −20°C before use, following the product recommendation.
• Solution preparation: The product information reports solubility of at least 30.1 mg/mL in DMSO and at least 50 mg/mL in water; prepare fresh solutions immediately before exposure because solution stability is limited.
• Solubilization support: Warming to 37°C or using an ultrasonic bath is suggested for difficult dissolution; confirm that the final solvent exposure is compatible with the cells.
• Valvular benchmark: The reference experiment used 10 and 100 μM p-cresyl sulfate in isolated porcine valvular interstitial cells for 7 days; reproduce these values only when the same model and endpoint are intended.
• Pathway modulation: The reference study used klotho at 100 pM, PX-478 at 0.5 μM, and SRT1720 at 1 mM during the reported 7-day cell treatments; these parameters are literature conditions rather than general protocol recommendations.
• Endothelial assay design: Test a justified concentration series and measure proliferation, wound closure, and viability in parallel; include albumin-matched conditions when modeling protein binding.
• Renal-failure model: Compare urinary excretion and exposure profiles between renal-function groups, and report the sampling schedule and renal phenotype rather than treating altered clearance as an assumed outcome.

For data integration, report both concentration units and exposure duration. A 10 μM cell treatment for 7 days cannot be directly equated with a single plasma measurement. Likewise, a change in urinary excretion is a pharmacokinetic observation and does not alone identify the responsible transporter, binding process, or tissue mechanism.

Conclusion & Outlook

p-Cresyl sulfate, or p-tolyl hydrogen sulfate, is a chemically defined protein-bound uremic solute with applications in CKD and cardiovascular research. Current evidence supports two experimentally useful phenotypes: impaired endothelial proliferation and wound repair, and enhanced valvular interstitial cell calcification under specified conditions.

The 2026 study provides a mechanistic framework centered on HIF-1α, klotho, SIRT1-related regulation, NF-κB acetylation, and RUNX2. Its cell and rat findings support further testing of exposure, albumin binding, renal clearance, and valvular endpoints. They do not establish a human treatment or a clinical decision threshold.

Future work should preserve the distinctions between total and free solute, cell assay and organismal disease, and reagent solubility and solution stability. Used with those boundaries, p-Cresyl sulfate is a practical tool for endothelial dysfunction research, vascular complication studies, and uremic toxin clearance research.